Characteristics of the 203 clinical information packages released between March 2019 and March 2022
| Number of packages | |
| Total clinical information packages | 203 |
| By product type | |
| Small molecule drug | 137 (67%) |
| Biologic | 44 (22%) |
| Vaccine | 20 (10%) |
| Radiopharmaceutical | 2 (1%) |
| By decision date | |
| Before 2003 | 21 |
| 2003–2018 | 49 |
| 2019–present | 133 |
| By submission type | |
| New applications (NDS, NDS-NAS) | 137 |
| Supplemental applications (SNDS, SNDS-c) | 54 |
| Generic drug applications (ANDS) | 2 |
| Interim order | 10 |
| By authorisation type | |
| NOC | 191 |
| Authorised with conditions | 10 |
| NOD-W | 2 |
ANDS, abbreviated new drug submission; NDS, new drug submission; NDS-NAS, new drug submission-new active substance; NOC, notice of compliance; NOD-W, notice of deficiency-withdrawal; SNDS, supplement to a new drug submission; SNDS-c, supplement to a new drug submission containing confirmatory trials.